financetom
Business
financetom
/
Business
/
Kinaxis CEO to Retire at Year End; Search for a Successor is Underway
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kinaxis CEO to Retire at Year End; Search for a Successor is Underway
Aug 29, 2024 8:21 AM

05:24 PM EDT, 08/27/2024 (MT Newswires) -- Kinaxis ( KXSCF ) said Tuesday chief executive John Sicard will retire from the position on Dec. 31 after three decades with the supply-chain software company.

Sicard will continue as a consultant with Kinaxis ( KXSCF ) throughout 2025, and the board of directors has started searching for his replacement, the company said.

Chief Sales Officer Claire Rychlewski is also leaving the company for a new opportunity. She will stay until November to ensure a smooth transition.

The company added that it is maintaining its fiscal 2024 guidance provided during its second-quarter earnings release.

Kinaxis ( KXSCF ) shares closed up $2.45 to $156.74 on the Toronto Stock Exchange.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Novartis Agrees to Buy Synnovation Therapeutics Unit For Up to $3 Billion
Novartis Agrees to Buy Synnovation Therapeutics Unit For Up to $3 Billion
Mar 20, 2026
03:42 AM EDT, 03/20/2026 (MT Newswires) -- Novartis ( NVS ) said Friday it agreed to buy Pikavation Therapeutics, a Synnovation Therapeutics unit, for $2 billion upfront and up to $1 billion in milestone payments. The acquisition of Pikavation Therapeutics includes a portfolio of targeted enzyme inhibitors, featuring a lead oral drug currently undergoing early-to-mid-stage clinical trials for advanced solid...
Revolution Medicines Insider Sold Shares Worth $1,280,412, According to a Recent SEC Filing
Revolution Medicines Insider Sold Shares Worth $1,280,412, According to a Recent SEC Filing
Mar 20, 2026
04:29 AM EDT, 03/20/2026 (MT Newswires) -- Mark A Goldsmith, Director, President and Chief Executive Officer, on March 17, 2026, sold 12,871 shares in Revolution Medicines ( RVMD ) for $1,280,412. Following the Form 4 filing with the SEC, Goldsmith has control over a total of 999,606 common shares of the company, with 276,698 shares held directly and 722,908 controlled...
Guardian Metal Resources Prices Upsized $60 Million IPO
Guardian Metal Resources Prices Upsized $60 Million IPO
Mar 20, 2026
03:42 AM EDT, 03/20/2026 (MT Newswires) -- Guardian Metal Resources ( GMTL ) said late Thursday it priced its upsized $60 million initial public offering in the US. The exploration stage company is issuing 4.4 million American depositary shares, representing 22.2 million ordinary shares, at a price of $13.50 per ADS. Guardian Metal has granted underwriters a 45-day option to...
Revolution Medicines Insider Sold Shares Worth $455,919, According to a Recent SEC Filing
Revolution Medicines Insider Sold Shares Worth $455,919, According to a Recent SEC Filing
Mar 20, 2026
04:30 AM EDT, 03/20/2026 (MT Newswires) -- Margaret A Horn, Chief Operating Officer, on March 17, 2026, sold 4,583 shares in Revolution Medicines ( RVMD ) for $455,919. Following the Form 4 filing with the SEC, Horn has control over a total of 157,570 common shares of the company, with 157,570 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1628171/000161071726000129/xslF345X05/form4.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved